首页> 外国专利> IMP-1 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER

IMP-1 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER

机译:IMP-1癌基因作为肺癌的治疗靶标和预后指标

摘要

IMP-1 was abundantly expressed in the majority of lung-cancers examined. Positive immunostaining of IMP-1 was correlated with tumor size (pT-classification; P=0.0003), non-adenocarcinoma histology (P0.0001), low-histological grade (P=0.0001), and poor prognosis (P=0.0053). Suppression of IMP-1 expression with siRNA effectively suppressed growth of NSCLC cells. IMP-1 was able to bind to mRNAs encoding a variety of proteins involved in signal transduction, cell-cycle progression, cell adhesion and cytoskeleton, and various types of enzymatic activities. These results suggest that IMP-1 expression is likely to play important roles in lung cancer development and progression, and that IMP-1 is a prognostic marker and a promising therapeutic target for treatment of lung cancer.
机译:在大多数检查过的肺癌中,IMP-1大量表达。 IMP-1的阳性免疫染色与肿瘤大小(pT分类; P = 0.0003),非腺癌组织学(P <0.0001),组织学等级低(P = 0.0001)和预后不良(P = 0.0053)相关。用siRNA抑制IMP-1表达可有效抑制NSCLC细胞的生长。 IMP-1能够与编码与信号转导,细胞周期进程,细胞粘附和细胞骨架以及各种酶活性有关的多种蛋白质的mRNA结合。这些结果表明,IMP-1表达可能在肺癌的发展和进程中发挥重要作用,并且IMP-1是肺癌的预后标志物和有希望的治疗靶标。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号